Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)+

Oncogene volume 19, pages 1744–1751 (2000)Cite this article

Abstract

Translocations of the chromosomal locus 11q23 that disrupt the MLL gene (alternatively ALL-1 or HRX) are frequently found in children's leukemias. These events fuse the MLL amino terminus in frame with a variety of unrelated proteins. Up to date, 16 different fusion partners have been characterized and more are likely to exist. No general unifying property could yet be detected amongst these proteins. We show here that the frequent MLL fusion partner ENL at 19p13.1 interacts with the human homologue of the mouse Abl-Interactor 1 (ABI1) protein. ABI1 in turn, is fused to MLL in the t(10;11)(p11.2;q23) translocation. ABI1 was identified as an ENL binding protein by a yeast two-hybrid screen. The interaction of ENL and ABI1 could be verified in vitro by far-Western blot assays and GST-pulldown studies as well as in vivo by co-immunoprecipitation experiments. A structure-function analysis identified an internal region of ENL and a composite motif of ABI1 including an SH3 domain as mutual binding partners. These data introduce novel aspects that might contribute to the understanding of the process of leukemogenesis by MLL fusion proteins.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 4
Figure 2
Figure 3

Similar content being viewed by others

References

  • Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ . 1990 J Mol Biol 215: 403–410

  • Bernard O and Berger R . 1995 Genes Chrom Cancer 13: 75–85

  • Bernard OA, Mauchauffe M, Mecucci C, Van den Berghe H and Berger R . 1994 Oncogene 9: 1039–1045

  • Biesova Z, Piccoli C and Wong WT . 1997 Oncogene 14: 233–241

  • Carapeti M, Aguiar RCT, Goldman JM and Cross NCP . 1998 Blood 91: 3127–3133

  • Chaplin TC, Ayton P, Bernard OA, Saha V, Della Valle V, Hillion J, Gregorini A, Lillington D, Berger R and Young BD . 1995 Blood 85: 1435–1441

  • Cleary ML . 1991 Cell 66: 619–622

  • Corral J, Lavenir I, Impey L, Warren AJ, Forster A, Larson TA, Bell S, McKenzie ANJ, King G and Rabbitts TH . 1996 Cell 85: 853–861

  • Djabali M, Selleri L, Parry P, Bower M, Young BD and Evans GA . 1992 Nat Genet 2: 113–118

  • Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J, Smith AJH and Rabbits TH . 1999 EMBO J 18: 3564–3574

  • Eissenberg JC, Elgin SCR and Paro R . 1995 IRL Press at Oxford University Press Oxford, UK pp 147–165

  • Gu Y, Nakamura T, Alder H, Pasad R, Canaani O, Cimino G, Croce CM and Canaani E . 1992 Cell 71: 701–708

  • Hillion J, Le Coniat M, Jonveaux P, Berger R and Bernard OA . 1997 Blood 90: 3714–3719

  • Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, Ohki M and Hayashi Y . 1997 Blood 90: 4699–4704

  • James P, Halladay J and Craig EA . 1996 Genetics 144: 1425–1436

  • Lavau C, Szilvassy SJ, Slany R and Cleary ML . 1997 EMBO J 16: 4226–4237

  • Look TA . 1997 Science 278: 1059–1064

  • Megonigal MD, Rappaport EF, Jones DH, Williams TM, Lovett BD, Kelly KM, Lerou PH, Moulton T, Budarf ML and Felix CA . 1998 Proc Natl Acad Sci USA 95: 6413–6418

  • Nakamura T, Alder H, Gu Y, Prasad R, Canaani O, Kamada N, Gale RP, Lange B, Crist WM, Nowell PC, Croce CM and Canaani E . 1993 Proc Natl Acad Sci USA 90: 4631–4635

  • Osaka M, Rowley JD and Zeleznik-Le NJ . 1999 Proc Natl Acad Sci USA 96: 6428–6433

  • Parry P, Wie Y and Evans G . 1994 Genes Chrom Cancer 11: 79–84

  • Prasad R, Gu Y, Alder H, Nakamura T, Canaani O, Saito H, Huebner K, Gale RP, Nowell PC, Kuriyama K, Miyazaki Y, Croce CM and Canaani E . 1993 Cancer Res 53: 5624–5628

  • Prasad R, Leshkowitz D, Gu Y, Alder H, Nakamura T, Saito H, Huebner K, Berger R, Croce CM and Canaani E . 1994 Proc Natl Acad Sci USA 91: 8107–8111

  • Rogaia D, Grignani F, Carbone R, Riganelli D, LoCoco F, Nakamura T, Croce CM, DiFiore P and Pelicci PJ . 1997 Cancer Res 57: 799–802

  • Rubnitz JE, Morrissey J, Savage PA and Cleary ML . 1994 Blood 84: 1747–1752

  • Shi Y, Alin K and Goff SP . 1995 Genes Dev 9: 2583–2597

  • Slany RK, Lavau C and Cleary ML . 1998 Mol Cell Biol 18: 122–129

  • So CW, Caldas C, Liu MM, Chen SJ, Huang QH, Gu LJ, Sham MH, Wiedemann LM and Chan LC . 1997 Proc Natl Acad Sci USA 94: 2563–2568

  • Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JA and Zelezni-Le NJ . 1997 Proc Natl Acad Sci USA 94: 8732–8737

  • Taki T, Shibuya N, Taniwaki M, Hanada R, Morishita K, Bessho F, Yanagisawa M and Hayashi Y . 1998 Blood 92: 1125–1130

  • Thirman MJ, Levitan DA, Kobayashi H, Simon MC and Rowley J . 1994 Proc Natl Acad Sci USA 91: 12110–12114

  • Tkachuk DC, Kohler S and Cleary ML . 1992 Cell 71: 691–700

  • Waring PM and Cleary ML . 1997 Curr Top Microbiol Immunol 220: 1–23

  • Yagi H, Deguchi K, Aono A, Tani Y, Kishimoto T and Komori T . 1998 Blood 92: 108

  • Yano T, Nakamura T, Blechman J, Sorio C, Dang CV, Geiger B and Canaani E . 1997 Proc Natl Acad Sci USA 94: 7286–7291

  • Yu BD, Hanson RD, Hess JL, Horning SE and Korsmeyer SJ . 1998 Proc Natl Acad Sci USA 95: 10632–10636

  • Yu BD, Hess JL, Horning SE, Brown GA and Korsmeyer SJ . 1995 Nature 378: 505–508

  • Ziemin van der Poel S, McCabe NR, Gill HJ, Espinosa III Y, Patel Y, Harden A, Rubinelli P, Smith SD, Le Beau MM, Rowley JD and Diaz MO . 1991 Proc Natl Acad Sci USA 88: 10735–10739

  • Ziemnicka-Kotula D, Xu J, Gu H, Potempska A, Kim KS, Jenkins EC, Trenkner E and Kotula L . 1998 J Biol Chem 273: 13681–13692

Download references

Acknowledgements

This work was supported by grants from the DFG (SL27/2-1; SFB466-C7) and the Johannes und Frieda Marohn Stiftung (SLA98). MP García-Cuéllar was supported by a postdoctoral fellowship ‘Beca del Ministerio de Educación y Ciencia: Programa de Formación de Personal Investigador en el Extranjero, Spain.’

Author information

Authors and Affiliations

  1. Department of Genetics, University of Erlangen, Staudtstrasse 5, Erlangen, 91058, Germany

    M P García-Cuéllar, S A Schreiner, M Birke, M Hamacher, G H Fey & R K Slany

Authors
  1. M P García-Cuéllar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S A Schreiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Birke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Hamacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G H Fey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R K Slany
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

García-Cuéllar, M., Schreiner, S., Birke, M. et al. ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)+. Oncogene 19, 1744–1751 (2000). https://doi.org/10.1038/sj.onc.1203506

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203506

Keywords

This article is cited by

Search

Advanced search

Quick links